eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
5/2009
vol. 13
 
Share:
Send email
Share:
abstract:
Original paper

The comparison of response to palliative chemotherapy with mitoxantrone + prednisone versus docetaxel + prednisone in patients with disseminated hormone-refractory prostate cancer

Grzegorz Świątoniowski
,
Marcin Ekiert
,
Katarzyna Soter
,
Krzysztof Rogala
,
Anna Jakieła
,
Piotr Dzięgiel

Współczesna Onkologia (2009) vol. 13; 5 (262–264)
Online publish date: 2009/11/18
View full text Get citation
 
Introduction: Some patients with disseminated, hormone-refractory prostate cancer (HRPC) are treated with palliative chemotherapy which, if based on mitoxantrone, can improve the quality of life and influences PSA decrease. However, it does not influence the overall survival. Such influence has been reported with the use of docetaxel-based therapy.
Aim of the study: To compare the response to palliative chemotherapy with mitoxantrone with prednisone vs. docetaxel with prednisone used in HRPC.
Material and methods: The retrospective analysis included 51 males with disseminated HRPC treated with chemotherapy. The age of patients ranged from 51 to 86 years (median 69). Two therapeutic protocols – mitoxantrone with prednisone and docetaxel with prednisone (n = 21) – were implemented. The obtained responses to treatment and the potential predictive significance of factors such as age, performance status before treatment, initial level of PSA and haemoglobin were evaluated.
Results: In the mitoxantrone group 63.3% responses and in the docetaxel group 76.2% were observed. A significant difference in percentage response between groups was not observed (p = 0.2540). No significant influence of the examined parameters was observed.
Conclusion: Chemotherapy in patients with HRPC is an effective therapeutic treatment using mitoxantrone or docetaxel (both with prednisone).
keywords:

prostate cancer, chemo-therapy, docetaxel, mitoxantrone
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.